Enhancing neuronal plasticity and cellular resilience to develop novel, improved therapeutics for difficult-to-treat depression

Husseini K. Manji, Jorge A. Quiroz, Jonathan Sporn, Jennifer Payne, Kirk Denicoff, Neil A. Gray, Carlos A. Zarate, Dennis S. Charney

Research output: Contribution to journalArticle

Abstract

There is growing evidence from neuroimaging and post-mortem studies that severe mood disorders, which have traditionally been conceptualized as neurochemical disorders, are associated with impairments of structural plasticity and cellular resilience. It is thus noteworthy that recent preclinical studies have shown that critical molecules in neurotrophic signaling cascades (most notably cyclic adenosine monophosphate [cAMP] response element binding protein, brain-derived neurotrophic factor, bcl-2, and mitogen activated protein [MAP] kinases) are long-term targets for antidepressant agents and antidepressant potentiating modalities. This suggests that effective treatments provide both trophic and neurochemical support, which serves to enhance and maintain normal synoptic connectivity, thereby allowing the chemical signal to reinstate the optimal functioning of critical circuits necessary for normal affective functioning. For many refractory patients, drugs mimicking "traditional" strategies, which directly or indirectly alter monoaminergic levels, may be of limited benefit. Newer "plasticity enhancing" strategies that may have utility in the treatment of refractory depression include N-methyl-o-aspartate antagonists, alpha-amino-3-hydroxy-5- methylisoxazole propionate (AMPA) potentiators, cAMP phosphodiesterase inhibitors, and glucocorticoid receptor antagonists. Small-molecule agents that regulate the activity of growth factors, MAP kinases cascades, and the bcl-2 family of proteins are also promising future avenues. The development of novel, nonaminergic-based therapeutics holds much promise for improved treatment of severe, refractory mood disorders.

Original languageEnglish (US)
Pages (from-to)707-742
Number of pages36
JournalBiological Psychiatry
Volume53
Issue number8
DOIs
StatePublished - Apr 15 2003
Externally publishedYes

Fingerprint

Neuronal Plasticity
Depression
Mood Disorders
Cyclic AMP
Antidepressive Agents
Treatment-Resistant Depressive Disorder
Phosphodiesterase Inhibitors
Mitogen-Activated Protein Kinase 1
Brain-Derived Neurotrophic Factor
Glucocorticoid Receptors
Propionates
Response Elements
Therapeutics
Mitogen-Activated Protein Kinases
Aspartic Acid
Neuroimaging
Intercellular Signaling Peptides and Proteins
Carrier Proteins
Pharmaceutical Preparations
Proteins

Keywords

  • Bcl-2
  • Brain-derived neurotrophic factor
  • Glutamate
  • Lithium
  • Mitogen activated protein kinase
  • Neuroplasticity

ASJC Scopus subject areas

  • Biological Psychiatry

Cite this

Enhancing neuronal plasticity and cellular resilience to develop novel, improved therapeutics for difficult-to-treat depression. / Manji, Husseini K.; Quiroz, Jorge A.; Sporn, Jonathan; Payne, Jennifer; Denicoff, Kirk; Gray, Neil A.; Zarate, Carlos A.; Charney, Dennis S.

In: Biological Psychiatry, Vol. 53, No. 8, 15.04.2003, p. 707-742.

Research output: Contribution to journalArticle

Manji, Husseini K. ; Quiroz, Jorge A. ; Sporn, Jonathan ; Payne, Jennifer ; Denicoff, Kirk ; Gray, Neil A. ; Zarate, Carlos A. ; Charney, Dennis S. / Enhancing neuronal plasticity and cellular resilience to develop novel, improved therapeutics for difficult-to-treat depression. In: Biological Psychiatry. 2003 ; Vol. 53, No. 8. pp. 707-742.
@article{9af43e734b3e45bdae29f17af91e3b44,
title = "Enhancing neuronal plasticity and cellular resilience to develop novel, improved therapeutics for difficult-to-treat depression",
abstract = "There is growing evidence from neuroimaging and post-mortem studies that severe mood disorders, which have traditionally been conceptualized as neurochemical disorders, are associated with impairments of structural plasticity and cellular resilience. It is thus noteworthy that recent preclinical studies have shown that critical molecules in neurotrophic signaling cascades (most notably cyclic adenosine monophosphate [cAMP] response element binding protein, brain-derived neurotrophic factor, bcl-2, and mitogen activated protein [MAP] kinases) are long-term targets for antidepressant agents and antidepressant potentiating modalities. This suggests that effective treatments provide both trophic and neurochemical support, which serves to enhance and maintain normal synoptic connectivity, thereby allowing the chemical signal to reinstate the optimal functioning of critical circuits necessary for normal affective functioning. For many refractory patients, drugs mimicking {"}traditional{"} strategies, which directly or indirectly alter monoaminergic levels, may be of limited benefit. Newer {"}plasticity enhancing{"} strategies that may have utility in the treatment of refractory depression include N-methyl-o-aspartate antagonists, alpha-amino-3-hydroxy-5- methylisoxazole propionate (AMPA) potentiators, cAMP phosphodiesterase inhibitors, and glucocorticoid receptor antagonists. Small-molecule agents that regulate the activity of growth factors, MAP kinases cascades, and the bcl-2 family of proteins are also promising future avenues. The development of novel, nonaminergic-based therapeutics holds much promise for improved treatment of severe, refractory mood disorders.",
keywords = "Bcl-2, Brain-derived neurotrophic factor, Glutamate, Lithium, Mitogen activated protein kinase, Neuroplasticity",
author = "Manji, {Husseini K.} and Quiroz, {Jorge A.} and Jonathan Sporn and Jennifer Payne and Kirk Denicoff and Gray, {Neil A.} and Zarate, {Carlos A.} and Charney, {Dennis S.}",
year = "2003",
month = "4",
day = "15",
doi = "10.1016/S0006-3223(03)00117-3",
language = "English (US)",
volume = "53",
pages = "707--742",
journal = "Biological Psychiatry",
issn = "0006-3223",
publisher = "Elsevier USA",
number = "8",

}

TY - JOUR

T1 - Enhancing neuronal plasticity and cellular resilience to develop novel, improved therapeutics for difficult-to-treat depression

AU - Manji, Husseini K.

AU - Quiroz, Jorge A.

AU - Sporn, Jonathan

AU - Payne, Jennifer

AU - Denicoff, Kirk

AU - Gray, Neil A.

AU - Zarate, Carlos A.

AU - Charney, Dennis S.

PY - 2003/4/15

Y1 - 2003/4/15

N2 - There is growing evidence from neuroimaging and post-mortem studies that severe mood disorders, which have traditionally been conceptualized as neurochemical disorders, are associated with impairments of structural plasticity and cellular resilience. It is thus noteworthy that recent preclinical studies have shown that critical molecules in neurotrophic signaling cascades (most notably cyclic adenosine monophosphate [cAMP] response element binding protein, brain-derived neurotrophic factor, bcl-2, and mitogen activated protein [MAP] kinases) are long-term targets for antidepressant agents and antidepressant potentiating modalities. This suggests that effective treatments provide both trophic and neurochemical support, which serves to enhance and maintain normal synoptic connectivity, thereby allowing the chemical signal to reinstate the optimal functioning of critical circuits necessary for normal affective functioning. For many refractory patients, drugs mimicking "traditional" strategies, which directly or indirectly alter monoaminergic levels, may be of limited benefit. Newer "plasticity enhancing" strategies that may have utility in the treatment of refractory depression include N-methyl-o-aspartate antagonists, alpha-amino-3-hydroxy-5- methylisoxazole propionate (AMPA) potentiators, cAMP phosphodiesterase inhibitors, and glucocorticoid receptor antagonists. Small-molecule agents that regulate the activity of growth factors, MAP kinases cascades, and the bcl-2 family of proteins are also promising future avenues. The development of novel, nonaminergic-based therapeutics holds much promise for improved treatment of severe, refractory mood disorders.

AB - There is growing evidence from neuroimaging and post-mortem studies that severe mood disorders, which have traditionally been conceptualized as neurochemical disorders, are associated with impairments of structural plasticity and cellular resilience. It is thus noteworthy that recent preclinical studies have shown that critical molecules in neurotrophic signaling cascades (most notably cyclic adenosine monophosphate [cAMP] response element binding protein, brain-derived neurotrophic factor, bcl-2, and mitogen activated protein [MAP] kinases) are long-term targets for antidepressant agents and antidepressant potentiating modalities. This suggests that effective treatments provide both trophic and neurochemical support, which serves to enhance and maintain normal synoptic connectivity, thereby allowing the chemical signal to reinstate the optimal functioning of critical circuits necessary for normal affective functioning. For many refractory patients, drugs mimicking "traditional" strategies, which directly or indirectly alter monoaminergic levels, may be of limited benefit. Newer "plasticity enhancing" strategies that may have utility in the treatment of refractory depression include N-methyl-o-aspartate antagonists, alpha-amino-3-hydroxy-5- methylisoxazole propionate (AMPA) potentiators, cAMP phosphodiesterase inhibitors, and glucocorticoid receptor antagonists. Small-molecule agents that regulate the activity of growth factors, MAP kinases cascades, and the bcl-2 family of proteins are also promising future avenues. The development of novel, nonaminergic-based therapeutics holds much promise for improved treatment of severe, refractory mood disorders.

KW - Bcl-2

KW - Brain-derived neurotrophic factor

KW - Glutamate

KW - Lithium

KW - Mitogen activated protein kinase

KW - Neuroplasticity

UR - http://www.scopus.com/inward/record.url?scp=0038147541&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0038147541&partnerID=8YFLogxK

U2 - 10.1016/S0006-3223(03)00117-3

DO - 10.1016/S0006-3223(03)00117-3

M3 - Article

VL - 53

SP - 707

EP - 742

JO - Biological Psychiatry

JF - Biological Psychiatry

SN - 0006-3223

IS - 8

ER -